Literature DB >> 22493797

Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.

Jihua Liu1, Pavla Kopečková, Huaizhong Pan, Monika Sima, Patrick Bühler, Philipp Wolf, Ursula Elsässer-Beile, Jindřich Kopeček.   

Abstract

Biodistribution, pharmacokinetics, and efficacy of prostate-cancer-targeted HPMA copolymer/DTX conjugates are evaluated in nude mice bearing prostate cancer C4-2 xenografts. PSMA-specific monoclonal antibodies 3F/11 are used as the targeting moiety. Control conjugates tumor accumulation to total background organs (heart, lung, kidney, liver, spleen and blood) accumulation increase substantially with time for the targeted conjugate, and the ratio at 48 h is 7-fold higher than that at 6 h. Preliminary evaluation of the efficacy of the conjugates in vivo show tumor growth inhibition for all HPMA copolymer/DTX conjugates.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22493797      PMCID： PMC4605348          DOI： 10.1002/mabi.201100340

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN： 1616-5187            Impact factor:   4.979


  55 in total

1.  Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.

Authors:  Anil K Patri; Andrzej Myc; James Beals; Thommey P Thomas; Neil H Bander; James R Baker
Journal:  Bioconjug Chem       Date:  2004 Nov-Dec       Impact factor: 4.774

2.  Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Authors:  Shankar Vallabhajosula; Stanley J Goldsmith; Lale Kostakoglu; Mathew I Milowsky; David M Nanus; Neil H Bander
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

3.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

4.  A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.

Authors:  Ursula Elsässer-Beile; Philipp Wolf; Dorothee Gierschner; Patrick Bühler; Wolfgang Schultze-Seemann; Ulrich Wetterauer
Journal:  Prostate       Date:  2006-09-15       Impact factor: 4.104

Review 5.  Prostate-specific membrane antigen.

Authors:  W R Fair; R S Israeli; W D Heston
Journal:  Prostate       Date:  1997-07-01       Impact factor: 4.104

6.  Soluble biomedical polymers.

Authors:  J Kopecek
Journal:  Polim Med       Date:  1977

7.  A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.

Authors:  Saurabh Aggarwal; Pratap Singh; Ozlem Topaloglu; John T Isaacs; Samuel R Denmeade
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

8.  Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts.

Authors:  J J Shiah; Y Sun; C M Peterson; J Kopecek
Journal:  J Control Release       Date:  1999-08-27       Impact factor: 9.776

9.  Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

Authors:  Shankar Vallabhajosula; Stanley J Goldsmith; Klaus A Hamacher; Lale Kostakoglu; Shota Konishi; Mathew I Milowski; David M Nanus; Neil H Bander
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

10.  Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats.

Authors:  Song-Qi Gao; Yongen Sun; Pavla Kopecková; C Matthew Peterson; Jindrich Kopecek
Journal:  Pharm Res       Date:  2007-10-11       Impact factor: 4.200
View more
  3 in total

1.  HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.

Authors:  Yan Zhou; Jiyuan Yang; Johng S Rhim; Jindřich Kopeček
Journal:  J Control Release       Date:  2013-09-14       Impact factor: 9.776

2.  Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.

Authors:  Zheng-Hong Peng; Monika Sima; Mohamed E Salama; Pavla Kopečková; Jindřich Kopeček
Journal:  J Drug Target       Date:  2013-12       Impact factor: 5.121

3.  A Nanostrategy for Efficient Imaging-Guided Antitumor Therapy through a Stimuli-Responsive Branched Polymeric Prodrug.

Authors:  Hao Cai; Xinghang Dai; Xiaoming Wang; Ping Tan; Lei Gu; Qiang Luo; Xiuli Zheng; Zhiqian Li; Hongyan Zhu; Hu Zhang; Zhongwei Gu; Qiyong Gong; Kui Luo
Journal:  Adv Sci (Weinh)       Date:  2020-01-31       Impact factor: 16.806
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.